AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24587006 — intervention group
Group type: COMPARATOR
Intervention: Intravenous palonosetron
Number of subjects: 25
Study 21769988 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the association between cognitive problems and chemotherapy
Number of subjects: 150
Study 21769988 — intervention group
Group type: COMPARATOR
Intervention: No information about the association between cognitive problems and chemotherapy
Number of subjects: 150
Study 19540633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing student mentoring programs
Number of subjects: 0
Study 18093331 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (8 weekly lessons, support by e-mail)
Number of subjects: 0
Study 18093331 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving therapy (5 weekly lessons, support by e-mail)
Number of subjects: 0
Study 18093331 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (receives intervention 3 months later)
Number of subjects: 0
Study 16357163 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF treatment in pancreatic cancer cells with G691S RET polymorphism
Number of subjects: 0
Study 16357163 — intervention group
Group type: COMPARATOR
Intervention: GDNF treatment in pancreatic cancer cells without specific mention of RET polymorphism
Number of subjects: 0
Study 11984746 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 123319 (8 microg/minute)
Number of subjects: 8
Study 11984746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10919583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g twice daily
Number of subjects: 150
Study 10919583 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1-3 mg/kg daily
Number of subjects: 150
Study 10919583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 150
Study 10919583 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 150
Study 9044338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dialysate sodium (140 meq/dl) and fixed ultrafiltration rate (Protocol A)
Number of subjects: 10
Study 9044338 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable sodium dialysate (160-140 meq/dl) and variable ultrafiltration (Protocol B)
Number of subjects: 10
Study 1526096 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. immunoglobulins and oral polyvalent bacterial vaccine
Number of subjects: 90
Study 1526096 — intervention group
Group type: EXPERIMENTAL
Intervention: vaccine only
Number of subjects: 90
Study 1526096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 90
Study 2862594 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 153
Study 2862594 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen)
Number of subjects: 153
Study 2862594 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF + T
Number of subjects: 153
Study 31295708 — intervention group
Group type: EXPERIMENTAL
Intervention: Online multi-component positive psychology intervention over 8 weeks
Number of subjects: 128
Study 31295708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 29154271 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue biopsies from AD patients
Number of subjects: 80
Study 29154271 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous adipose tissue biopsies from cognitively healthy proxies
Number of subjects: 80
Study 26328542 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based core stability exercises
Number of subjects: 31
Study 26328542 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based core stability exercises
Number of subjects: 31
Study 26328542 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 24041789 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5‐µg dose of A/Vietnam vaccine
Number of subjects: 0
Study 24041789 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster immunization with A/Indonesia(H5N1) vaccine
Number of subjects: 0
Study 22435937 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-high-density lipoprotein cholesterol
Number of subjects: 1173
Study 20085866 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nucleosome levels before therapy cycles 2 and 3
Number of subjects: 134
Study 20085866 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nucleosome levels before the second cycle
Number of subjects: 134
Study 20085866 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nucleosome levels before cycle 2
Number of subjects: 134
Study 17658394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide
Number of subjects: 777
Study 17658394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 777
Study 17658394 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777
Study 16259492 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based empowerment patient education program
Number of subjects: 0
Study 16259492 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly support group or monthly phone call from a nurse (follow-up conditions)
Number of subjects: 0
Study 16259492 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 0
Study 12106618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 microg, twice daily for 6 weeks)
Number of subjects: 440
Study 12106618 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast (20 mg, twice daily for 6 weeks)
Number of subjects: 440
Study 10403584 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI diet (51% CHO, 23% fat, 43 GI units)
Number of subjects: 21
Study 10403584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-mono high-GI diet (42% CHO, 35% fat, 59 GI units)
Number of subjects: 21
Study 10403584 — intervention group
Group type: COMPARATOR
Intervention: High-GI diet (53% CHO, 21% fat, 63 GI units)
Number of subjects: 21
Study 7673961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with relapsing remitting multiple sclerosis experiencing a relapse.
Number of subjects: 89
Study 7673961 — intervention group
Group type: COMPARATOR
Intervention: Control group of patients matched for age, sex, and degree of disability who did not experience clinical exacerbations during the same period.
Number of subjects: 89
Study 2405895 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 44
Study 2405895 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 44
Study 31900245 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic supracervical hysterectomy
Number of subjects: 0
Study 31900245 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation
Number of subjects: 0
Study 31313336 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cadmium (U‐Cd)
Number of subjects: 288
Study 31313336 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cadmium (B‐Cd)
Number of subjects: 288
Study 31313336 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cadmium (U‐Cd) at 95th percentile cut-off
Number of subjects: 288
Study 31313336 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cadmium (B‐Cd) at 95th percentile cut-off
Number of subjects: 288
Study 31313336 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cadmium (U‐Cd) at 90th percentile cut-off
Number of subjects: 288
Study 31313336 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cadmium (B‐Cd) at 90th percentile cut-off
Number of subjects: 288
Study 28542868 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml lidocaine 2%
Number of subjects: 16
Study 28542868 — intervention group
Group type: COMPARATOR
Intervention: 15 ml saline
Number of subjects: 16
Study 25906348 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 1573
Study 25906348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1573
Study 23869370 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (test group)
Number of subjects: 30
Study 23869370 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading (control group)
Number of subjects: 30
Study 21585062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-moxibustion treatment (12 weeks, once every other day, main acupoints: Feishu, Geshu, Ganshu, Pishu, Shenshu; moxibustion applied for about 3 min each time)
Number of subjects: 60
Study 21585062 — intervention group
Group type: COMPARATOR
Intervention: Medication group (oral Acitretin capsules, 20 mg/d for 12 weeks)
Number of subjects: 60
Study 19175613 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan
Number of subjects: 41
Study 19175613 — intervention group
Group type: COMPARATOR
Intervention: Non-specific treatment
Number of subjects: 41
Study 17313602 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal STS device
Number of subjects: 206
Study 17313602 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 206
Study 14742356 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin regimen with a bolus of 1 x 10(6) kallikrein inhibiting units (KIU) before CPB, 1 x 10(6) KIU in the priming solution, and a continuous infusion of 250,000 KIU/h during CPB.
Number of subjects: 200
Study 14742356 — intervention group
Group type: COMPARATOR
Intervention: Heparin management according to Hepcon HMS Plus.
Number of subjects: 200
Study 11476127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-60 mg/day)
Number of subjects: 157
Study 11476127 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (75-375 mg/day, twice a day)
Number of subjects: 157
Study 11476127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 157
Study 11476127 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 157
Study 11476127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 157
Study 9782221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (D) 500 mg once daily for 5 days
Number of subjects: 46
Study 8156516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 1 after CY
Number of subjects: 108
Study 8156516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 9 after CY
Number of subjects: 108
Study 8156516 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard doses of chemotherapy)
Number of subjects: 108
Study 3058555 — intervention group
Group type: EXPERIMENTAL
Intervention: De‐Nol (colloidal bismuth subcitrate) for eight weeks
Number of subjects: 66
Study 3058555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31094587 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-measured sedentary behaviour
Number of subjects: 233
Study 30762217 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic suprapectoral intraosseous implant-free biceps tenodesis (ASIIBT) with Cobra Guide (CG)
Number of subjects: 58
Study 30762217 — intervention group
Group type: COMPARATOR
Intervention: Suture anchors (SA)
Number of subjects: 58
Study 30762217 — intervention group
Group type: COMPARATOR
Intervention: Interference screws (IS)
Number of subjects: 58
Study 30144894 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 31
Study 30144894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 28543286 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from rhythm control to rate control (594 patients)
Number of subjects: 4060
Study 28543286 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from rate control to rhythm control (248 patients)
Number of subjects: 4060
Study 28543286 — intervention group
Group type: COMPARATOR
Intervention: Crossover from rhythm control to rate control
Number of subjects: 4060
Study 28543286 — intervention group
Group type: COMPARATOR
Intervention: Crossover from rate control to rhythm control
Number of subjects: 4060
Study 26625506 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive ($8 per medication per month)
Number of subjects: 337
Study 26625506 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 337
Study 26625506 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive ($8 per medication per month) in diabetics
Number of subjects: 337
Study 26625506 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care) in diabetics
Number of subjects: 337
Study 26625506 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive ($8 per medication per month) in nondiabetics
Number of subjects: 337
Study 26625506 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care) in nondiabetics
Number of subjects: 337
Study 23847058 — intervention group
Group type: EXPERIMENTAL
Intervention: QIV
Number of subjects: 3094
Study 23847058 — intervention group
Group type: COMPARATOR
Intervention: TIV-Vic
Number of subjects: 3094
Study 23847058 — intervention group
Group type: COMPARATOR
Intervention: TIV-Yam
Number of subjects: 3094
Study 20498402 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy (RT)
Number of subjects: 807
Study 20498402 — intervention group
Group type: COMPARATOR
Intervention: No consolidation radiotherapy (RT)
Number of subjects: 807
Study 18951296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study 17348307 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 100
Study 17348307 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 100
Study 14638564 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (3 group sessions and telephone follow-up)
Number of subjects: 211
Study 10843169 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg)
Number of subjects: 16
Study 10843169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10843169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (run-in)
Number of subjects: 16
Study 8855526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-spray thrombolysis plus angioplasty
Number of subjects: 20
Study 8855526 — intervention group
Group type: COMPARATOR
Intervention: Surgical thrombectomy
Number of subjects: 20
Study 1735858 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagel (human collagen)
Number of subjects: 0
Study 1735858 — intervention group
Group type: COMPARATOR
Intervention: Healon (sodium hyaluronate)
Number of subjects: 0
Study 6369583 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nasogastric drainage avoided completely in 40 patients (nonintubated group)
Number of subjects: 52
Study 6369583 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative nasogastric aspiration
Number of subjects: 52
Study 30498835 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month reduced calorie diet at two protein levels
Number of subjects: 67
Study 27502800 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium with aromatherapy (2% rose essential oil)
Number of subjects: 100
Study 27502800 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg/im)
Number of subjects: 100
Study 24337978 — intervention group
Group type: EXPERIMENTAL
Intervention: QGC001 (10, 50, 125, 250, 500, 750, 1,000, and 1,250 mg)
Number of subjects: 56
Study 24337978 — intervention group
Group type: EXPERIMENTAL
Intervention: QGC001
Number of subjects: 56
Study 22395187 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with 2.0 g/L FOS
Number of subjects: 4
Study 22395187 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with 3.0 g/L FOS
Number of subjects: 4
Study 22395187 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available milk-based infant formula
Number of subjects: 4
Study 22395187 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 4
Study 20384757 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium 1,550‐nm fractional laser at 10 mJ
Number of subjects: 15
Study 20384757 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium 1,550‐nm fractional laser at 40 mJ
Number of subjects: 15
Study 20384757 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium 1,550‐nm fractional laser (both dosages)
Number of subjects: 15
Study 18399898 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MSNF)
Number of subjects: 40
Study 18399898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16036387 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (2 g/h)
Number of subjects: 0
Study 16036387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (270 microg/h) + Verapamil (0.2 mg/h)
Number of subjects: 0
Study 16036387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 0
Study 16036387 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (2 mmol) in vitro
Number of subjects: 0
Study 16036387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (0.25 mg/ml) in vitro
Number of subjects: 0
Study 16036387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%) in vitro
Number of subjects: 0
Study 12750099 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular Computerized Psychophysical Test (MCPT)
Number of subjects: 108
Study 12750099 — intervention group
Group type: COMPARATOR
Intervention: Amsler grid
Number of subjects: 108
Study 10550454 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 25 mg/day
Number of subjects: 277
Study 10550454 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 50 mg/day
Number of subjects: 277
Study 10550454 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 75 mg/day
Number of subjects: 277
Study 10550454 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (all doses)
Number of subjects: 277
Study 10550454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 8905799 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1,200 mg/day for 10 days
Number of subjects: 12
Study 8905799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8905799 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 12
Study 1991182 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (4 cigarettes an hour)
Number of subjects: 8
Study 1991182 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking (abstained for seven days or more)
Number of subjects: 8
Study 6140938 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118551 20 mg
Number of subjects: 6
Study 6140938 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118551 50 mg
Number of subjects: 6
Study 6140938 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 6
Study 6140938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30907785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-free, adhesive bone conduction device
Number of subjects: 13
Study 30907785 — intervention group
Group type: COMPARATOR
Intervention: Conventional bone conduction device
Number of subjects: 13
Study 30907785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 13
Study 28303364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (500 mL daily for one week)
Number of subjects: 30
Study 28303364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for one week after washout)
Number of subjects: 30
Study 25209368 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binding medication adherence intervention
Number of subjects: 112
Study 23473040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA anodal transcranial direct current stimulation (tDCS) for 10 min
Number of subjects: 13
Study 21844061 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium phosphate (1.6 mg/kg per day for 3 days)
Number of subjects: 84
Study 21844061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 18971132 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) pneumoperitoneum with 4% oxygen
Number of subjects: 22
Study 18971132 — intervention group
Group type: COMPARATOR
Intervention: CO(2) pneumoperitoneum (control)
Number of subjects: 22
Study 16492611 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (93.5% newly diagnosed, 6.5% treated)
Number of subjects: 301
Study 16492611 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 301
Study 12971032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg as intact tablets with water
Number of subjects: 18
Study 12971032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg as tablets crushed in acidic juice
Number of subjects: 18
Study 12971032 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 200 mg as intact tablets
Number of subjects: 18
Study 12971032 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying rate measured by radiolabeled technetium
Number of subjects: 18
Study 11685350 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU rehabilitation package (6-week self-help program including information and exercise)
Number of subjects: 61
Study 11685350 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up of ward visits and ICU clinic appointments
Number of subjects: 61
Study 9234872 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound device
Number of subjects: 60
Study 9234872 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 60
Study 8218758 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg each morning)
Number of subjects: 60
Study 8218758 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (40 mg at night time)
Number of subjects: 60